Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Mental Health & Depression — Weekly Report — November 9, 2026

Home/Health Insights/Mental Health & Depression — November 9 – November 16, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Mental Health & Depression
Updated Monday · November 16, 2026
Mental Health & Depression · November 9 – November 16, 2026

Mental Health & Depression
Weekly Report

This week's data 75 new clinical trials registered across 10 countries, with 3,265 trials actively recruiting patients worldwide.
Week of November 9 – November 16, 2026
  • 75 new clinical trials registered across 10 countries.
  • 3,265 trials actively recruiting patients worldwide.
  • Notable trial: Unveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by Depression (720 patients).
  • 1,620 new research papers published.
  • Top cited: "Antidepressant drug use in Europe: past consumption, prescribing patterns and forecast until 2030" (International Journal of Clinical Pharmacy, 5 citations).
  • Drug safety: Most reported effect across tracked medications (sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine) was Off Label Use.
  • 8 active drug recall alert(s) — see details below.

The week in numbers

Figures · November 9 – November 16, 2026
New Trials This Week
75.
registered Nov 9–Nov 16
Recruiting Now
3,265
active trials seeking patients
Countries
10
with active trials this week
Papers Published
1,620
new studies this week
Phase 3 Trials
0
late-stage trials this week
Fig. 01

Trials by country

Count · November 9 – November 16, 2026
United States
23
Turkey (Türkiye)
8
Not specified
6
United Kingdom
4
Spain
4
South Korea
3
France
3
Canada
3
China
2
Israel
1
0 6 12 18 23
total
Fig. 02

Trials by phase

Distribution · November 9 – November 16, 2026

New clinical trials registered this week for Mental Health & Depression. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

75 trials registered for Mental Health & Depression. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal Depression Mental Health & Depression · Rana Jawish (NCT07928908) Other Active Not Recruiting 100 United States
02 Melodies for Mums to Be: Community Group Singing Intervention for Pregnant Women With Antenatal Depressive Symptoms Mental Health & Depression · King's College London (NCT07935824) Other Not Yet Recruiting 50 United Kingdom
03 Dynamic Creative Arts Group Intervention to Alleviate Loneliness and Support Well-Being in Older Adults With Cognitive Changes Mental Health & Depression · Tel Aviv University (NCT07933029) Other Not Yet Recruiting 50 Israel
04 ALAS PROPIAS: BMGIM for Professionals Working in Intimate Partner Machista Violence Services Mental Health & Depression · Universidad Miguel Hernandez de Elche (NCT07925736) Other Active Not Recruiting 54 Spain
05 Effects of Mandala Coloring Before Gynecological Examination on Anxiety, Fear, and Pain Mental Health & Depression · Artvin Coruh University (NCT07928999) Other Not Yet Recruiting 60 Turkey (Türkiye)
06 Exploring Ketamine's Effects on Depression and Anxiety in Adults With Low Vision Mental Health & Depression · Stanford University (NCT07934043) Phase 2 Not Yet Recruiting 40 United States
07 Mild Cognitive Impairment in Older Adults With and Without Depressive Symptom Mental Health & Depression · University Medical Centre Maribor (NCT07931586) Other Not Yet Recruiting 60 Slovenia
08 Neurofeedback Training for Adolescents and Young Adults With Borderline Intellectual Functioning Mental Health & Depression · Seoul University of Buddhism (NCT07931183) Other Active Not Recruiting 13 South Korea
09 Study of Anxiety Free Experiences at the Dentist Mental Health & Depression · University of Texas Rio Grande Valley (NCT07931131) Other Recruiting 160 United States
10 The Mediating Role of Social Support and Self-Esteem in the Effect of Physical Activity on the Mental Health of University Students Mental Health & Depression · Bitlis Eren University (NCT07925346) Other Completed 484 Turkey (Türkiye)
11 Individualized Temporal Interference Stimulation for Reward Processing in Late-Life Depression Mental Health & Depression · Beijing HuiLongGuan Hospital (NCT07925047) Other Not Yet Recruiting 70 China
12 Effects of a Structured Expressive Arts Program Based on Cognitive Behavioral Therapy on Test Anxiety and Academic Self-Efficacy (Confidence in Academic Tasks) in Eleventh-Grade High School Students: A Randomized Controlled Study Mental Health & Depression · Ondokuz Mayıs University (NCT07934628) Other Completed 60 Turkey (Türkiye)
13 Effect of Nature-based Interventions on Mental Health and Markers of Inflammation in Women Victims of Violence Residing in the City of Bogotá Mental Health & Depression · Instituto Nacional de Salud, Colombia (NCT07935096) Other Completed 30 Colombia
14 A Controlled Study on Fighting Against Anxiety in Older People Through an Educational Audio Programme. Mental Health & Depression · Centre Hospitalier de Cannes Simone Veil (NCT07929987) Other Not Yet Recruiting 40 France
15 Enhancing the Effect of Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: A Double-blind Randomized Controlled Trial of Bupivacaine vs Bupivacaine + Ketamine Mental Health & Depression · The Royal's Institute of Mental Health Research (NCT07927036) Phase 2 Not Yet Recruiting 126 Canada
16 ALAS PROPIAS: Music Therapy for Women Experiencing Machista Violence in Intimate Partner Relationships Mental Health & Depression · Universidad Miguel Hernandez de Elche (NCT07925723) Other Active Not Recruiting 67 Spain
17 CYOA App Intervention for Social Media Use in Adolescents With Depression Mental Health & Depression · University of Minnesota (NCT07936890) Other Not Yet Recruiting 60 United States
18 Unveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by Depression Mental Health & Depression · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (NCT07932093) Other Recruiting 720 Germany
19 Safety, Tolerability and Efficacy of RGH-202 in Social Anxiety Disorder (STAGE) Mental Health & Depression · Gedeon Richter Plc. (NCT07931703) Phase 2 Not Yet Recruiting 156 United States
20 Halova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal Women Mental Health & Depression · Perfect Care Distribution (NCT07927088) Other Completed 150 Romania
21 Supporting Families of School-Aged Children With ADHD: A Dual-Generation Therapy Approach Through the BRIDGE Program Mental Health & Depression · University of Manitoba (NCT07926776) Other Not Yet Recruiting 30 Canada
22 The Impact of Peanuts on Brain Function in Young Adults Mental Health & Depression · William & Mary (NCT07930325) Other Recruiting 100 United States
23 The Effectiveness of Wearable Technology-Supported Gamification in Reducing Pain and Anxiety During Medical Procedures in Children: A Randomized Controlled Trial Mental Health & Depression · Bulent Ecevit University (NCT07930962) Other Enrolling By Invitation 60 Turkey (Türkiye)
24 Health Assessment in People With Severe Mental Illness Mental Health & Depression · University of the Basque Country (UPV/EHU) (NCT07931456) Other Recruiting 275 Spain
25 Effects of the Parents of Little Ones® - Baby Version® on Parenting Stress and Mindful Parenting in Postpartum Mothers Mental Health & Depression · University of Coimbra (NCT07932535) Other Not Yet Recruiting 264 Portugal
26 Virtual Reality Headset Intervention on Pain, Anxiety, and Vital Signs in Pregnant Women Following Vaccination Mental Health & Depression · Serpil Uyar (NCT07936305) Other Active Not Recruiting 200 Turkey (Türkiye)
27 Decentralized, Status Neutral, Stakeholder-engaged, Post-incarceration Intervention for People Living With and at Risk for HIV Mental Health & Depression · Montefiore Medical Center (NCT07927673) Other Not Yet Recruiting 420 United States
28 Psychodrama for Adults With Relapsing-Remitting Multiple Sclerosis: A Mixed-Methods Study Mental Health & Depression · Bahçeşehir University (NCT07928765) Other Completed 12 Turkey (Türkiye)
29 An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion Mental Health & Depression · Massachusetts General Hospital (NCT07923864) Other Not Yet Recruiting 260 United States
30 Aggression in Military Personnel Mental Health & Depression · James A. Haley Veterans Administration Hospital (NCT07931079) Other Not Yet Recruiting 106 N/A
31 The Effect of Virtual Reality Distraction on Anxiety, Pain, and Satisfaction in Patients Undergoing Cardiac Catheterization in Palestine Mental Health & Depression · Arab American University (Palestine) (NCT07934368) Other Completed 92 Palestinian Territories
32 Nurse-Led Self-Management Support After Coronary Artery Bypass Surgery Mental Health & Depression · University of Jordan (NCT07930819) Other Not Yet Recruiting 384 Jordan
33 The Effects of Laughter Yoga and Progressive Muscle Relaxation Exercises on Pregnancy Symptoms and Pregnancy-Related Anxiety in Primiparous Women in the First Trimester Mental Health & Depression · Selcuk University (NCT07927426) Other Recruiting 171 Turkey (Türkiye)
34 Healing Trauma Plus Mental Health & Depression · Envisioning Justice Solutions, Inc (NCT07926568) Other Completed 256 United States
35 Predicting Transitions From Depression to Wellbeing Through a Network-based Operationalization of Plasticity Mental Health & Depression · IRCCS San Raffaele (NCT07933276) Other Not Yet Recruiting 200 N/A
36 Effect of Therapeutic Storybook Series on Anxiety in Children Undergoing Chemotherapy Mental Health & Depression · Asmaa Rashad (NCT07936318) Other Active Not Recruiting 60 Egypt
37 Project Raising Exposure Awareness for Caregiver Help-Seeking Mental Health & Depression · Brown University (NCT07929077) Other Not Yet Recruiting 100 N/A
38 Mindfulness Meditation to Reduce Cognitive Load Mental Health & Depression · University of South Carolina (NCT07924904) Other Not Yet Recruiting 60 United States
39 Emotional Reactivity in Severe Alcohol Use Disorder and Major Depressive Disorder Using Eye-tracking, Physiological, and Interoceptive Measures (ERAD) Mental Health & Depression · Université Catholique de Louvain (NCT07925281) Other Recruiting 280 Belgium
40 The Effect of Virtual Reality Headset and Hand Massage on Pain, Anxiety, Patient Satisfaction, and Physiological Parameters in Patients Who Have Undergone Abdominal Surgery Mental Health & Depression · Dokuz Eylul University (NCT07929337) Other Not Yet Recruiting 66 Turkey (Türkiye)
41 Auricular Vagus Nerve Stimulation for Anxiety and Sleep Quality in Patients With Generalized Anxiety Disorder Mental Health & Depression · Birjand University of Medical Sciences (NCT07930871) Other Not Yet Recruiting 40 N/A
42 Exploring and Modifying BarrieRs to Enhance ACcess to Mental Health Support for Ethnic Minority Children and Young People in Acute Paediatric Settings. Mental Health & Depression · University of Leicester (NCT07934810) Other Not Yet Recruiting 90 United Kingdom
43 Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias Mental Health & Depression · Rhode Island Hospital (NCT07933367) Other Not Yet Recruiting 280 United States
44 Evaluation of the EPDS and PC-PTSD-5 Scales for Screening Postpartum Mental Health Disorders Among Migrant Women. Mental Health & Depression · Fondation Hôpital Saint-Joseph (NCT07929272) Other Not Yet Recruiting 80 France
45 Peer Recovery Support in the Homeless Health Care Setting Mental Health & Depression · Massachusetts General Hospital (NCT07931430) Other Not Yet Recruiting 40 N/A
46 Implementing Brain Health PRO Across Diverse Settings: A Multi-Site Implementation Study Mental Health & Depression · Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal (NCT07935629) Other Recruiting 434 Canada
47 Neurocomputational Training to Improve Reward Responsiveness in Veterans With Anhedonia Mental Health & Depression · VA Office of Research and Development (NCT07928310) Other Not Yet Recruiting 120 United States
48 Phase-Locked Accelerated Intermittent Theta Burst Stimulation for Treatment-Resistant Depression Mental Health & Depression · Cheng-Hsin General Hospital (NCT07930000) Other Completed 54 Taiwan
49 HALOA: Cardiac Coherence With CPAP for Obstructive Sleep Apnea Mental Health & Depression · Clinique du Millenaire (NCT07929064) Other Not Yet Recruiting 180 N/A
50 Efficacy and Neural Mechanisms of Individualized Neuromodulation Combined With Think/No-Think Training in Individuals With Internalizing Disorders Mental Health & Depression · Chunyan Zhu (NCT07935005) Other Not Yet Recruiting 150 China
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Mental Health & Depression. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
sertraline Nausea 961
fluoxetine Off Label Use 508
escitalopram Fatigue 726
venlafaxine Off Label Use 738
duloxetine Nausea 672

Recalls & safety notices

§ 05 · 8 items this week

FDA drug recall notices for medications related to Mental Health & Depression. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionU.S Nationwide StatusOngoing
Jul 15
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionNationwide in the US StatusOngoing
Dec 6
2024
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNationwide within the United States StatusOngoing
Nov 24
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionUS Nationwide. StatusOngoing
Apr 14
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionUS Nationwide. StatusOngoing
Apr 14
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNJ, AZ, IN StatusOngoing
Jul 25
2025
IIClass

DULOXETINE

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

ManufacturerAjanta Pharma Ltd. DistributionNationwide within U.S StatusOngoing
Apr 29
2026
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNationwide within the United States StatusOngoing
Nov 24
2025
§ 06

Published research

1,620 papers

Recently published peer-reviewed studies related to Mental Health & Depression, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Symptom Impact in Angelman Syndrome: Results from the Hope in Action Caregiver Survey. Peay HL et al. 10.1007/s40271-026-00855-w
View abstract

BACKGROUND AND OBJECTIVE: Angelman syndrome is a rare neurological disorder with no approved disease-modifying therapies. First-generation treatments are expected to be disease modifying but not curative, highlighting the importance of understanding symptoms with the greatest impact on individuals with Angelman syndrome and their caregivers to support patient-focused drug development. The Hope in Action survey was designed to capture lived experiences and inform an externally led, patient-focused drug development meeting. METHODS: A global online survey was conducted among primary caregivers of individuals with Angelman syndrome. The survey was developed by a multidisciplinary team with input from advocates, caregivers, and representatives of the US Food and Drug Administration. Caregivers ranked top-3 domains and rated related symptoms affecting individuals with Angelman syndrome and those impacting caregivers; and top-5 priority symptoms to address with a new non-curative therapeutic. Analyses were descriptive. RESULTS: When ranking and rating from lists of high-impact domains and symptoms, 370 caregiver participants most frequently identified communication, daily living skills, gross motor function, and cognition as impactful to individuals living with Angelman syndrome, and patients' independence and communication challenges as impactful to their own caregiver functioning, social participation, and mental health. Priority symptoms to treat with a new therapy included expressive communication, seizures, mobility, sleep, toileting, aggression, balance, and sustained attention/engagement. CONCLUSIONS: Through the largest caregiver-reported study on Angelman syndrome symptom impact, we demonstrate an unmet treatment need and a profound impact on individuals and caregivers across a multitude of domains. These findings directly inform patient-focused drug development and reflect alignment of caregiver priorities and outcome measure selection for trials.

The patient 2026 Nov 15 PubMed
02 [Assessment of neurocognitive decline in primary care practice]. Kabella B et al. 10.1556/650.2026.33684
View abstract

INTRODUCTION: Neurocognitive disorders pose a significant public health burden but often remain undetected at an early stage. Since several risk factors are modifiable, primary care plays a crucial role in prevention, screening, and management. OBJECTIVE: This study investigated the prevalence of cognitive decline and its associated demographic, lifestyle, health, and digital factors among patients aged 65 and older in a general practitioner practice in Budapest. METHOD: This cross-sectional study included 214 adult patients. Cognitive performance was measured using the education-adjusted Montreal Cognitive Assessment. Mood symptoms were assessed via the Hospital Anxiety and Depression Scale, while sociodemographic, lifestyle, health, and digital habits were recorded using a self-administered questionnaire. Data were analyzed using Spearman's rank correlation. RESULTS: The participants' mean age was 75.8 ± 7.2 years; 66.8% were women, and 59.8% held a college degree. The mean Montreal Cognitive Assessment score was 26.6 ± 2.5. Suspected cognitive impairment was identified in 29.9% of participants using the standard <26 cutoff, and in 9.4% using a stricter <24 cutoff. Montreal Cognitive Assessment scores correlated negatively with age, but showed significant positive associations with mobility, self-care, quality of life, better mood, good general health, subjective cognitive assessment, and daily digital device use (p<0.05). Education and chronic disease count showed no significant associations. DISCUSSION: Early-stage neurocognitive decline is highly prevalent in general practice and requires structured screening to be detected. The significant links between cognitive performance and functional, lifestyle, and digital factors highlight the necessity of a multifactorial approach. CONCLUSION: The Montreal Cognitive Assessment is an effective primary care screening tool. Our results emphasize the importance of comprehensive, lifestyle-oriented prevention. The link between digital device use and cognition could inspire computer-based screening, monitoring and training programs in primary care. Orv Hetil. 2026; 167(46): 1867-1875.

Orvosi hetilap 2026 Nov 15 PubMed
03 Structural brain abnormality, pharmacotherapy, and treatment resistant schizophrenia management: a systematic review and critical appraisal. de Bartolomeis A et al. 10.1080/14656566.2026.2763331
View abstract

INTRODUCTION: Treatment-resistant schizophrenia (TRS) affects up to 30% of patients with schizophrenia and carries a substantial burden, yet clozapine, the only antipsychotic specifically indicated, is delayed by years because resistance is recognized retrospectively. Neuroimaging may provide objective biomarkers to shorten this delay. METHODS: We searched PubMed and Scopus to June 2026 following PRISMA guidelines. We included peer-reviewed neuroimaging studies investigating TRS, covering structural, functional, and metabolic modalities; studies not addressing TRS were excluded. Risk of bias was assessed using ROBINS-I for non-randomized studies and RoB 2 for randomized trials. Findings were synthesized qualitatively, without meta-analysis. RESULTS: Of 1502 identified records, 1179 were screened and 94 studies were included (44 structural, 18 functional, and 32 metabolic). TRS was characterized by extensive abnormalities in frontal cortical, limbic, and white matter pathways and, compared with treatment-responsive schizophrenia (nTRS), by the absence of striatal dopaminergic hyperactivity, alongside functional and metabolic alterations in frontal and cortico-subcortical circuits. Evidence concerning ultra-treatment-resistant schizophrenia (uTRS) remains scarce. CONCLUSIONS: Neuroimaging findings support a distributed cortico-subcortical phenotype and a non-dopaminergic, potentially glutamatergic pathophysiology in TRS. However, the evidence remains constrained by small, heterogeneous, predominantly cross-sectional studies, with uTRS still poorly investigated. PROTOCOL REGISTRATION: PROSPERO (CRD420261437825).

Expert opinion on pharmacotherapy 2026 Nov 15 PubMed
04 Sparse Network And Component Analysis: A Tutorial on Estimating Cross-Domain Networks. Tio P et al. 10.1080/00273171.2026.2738738
View abstract

In network approaches to psychopathology, mental disorders arise out of the interactions between symptoms in a network structure. While these approaches were initially focused on individual psychopathological domains (e.g., how are depression symptoms connected), researchers increasingly include multiple domains in empirical analyses (augmenting psychological symptoms with physiological and brain data). Often, in such analyses all variables are analyzed simultaneously, without taking into account that the data originate from different domains. Such multi-domain networks contain both domain-specific and cross-domain relations. Typically, the cross-domain relations are of particular interest because these represent how domains are connected. However, estimating cross-domain relations presents problems since they are typically weaker than their domain-specific counterparts, such that standard estimation algorithms tend to exclude cross-domain relations. Previously, we have proposed that estimation of cross-domain relations can be improved by taking the multi-domain structure of the data into account using Sparse Network And Component (SNAC) analysis. In this paper, we provide a step-by-step tutorial on how to perform such analysis using the novel R Package .

Multivariate behavioral research 2026 Nov 15 PubMed
05 Acupuncture-Assisted Zolpidem Tartrate Tapering and Discontinuation in Patients with Chronic Insomnia Disorder Stabilized on Zolpidem: A Study Protocol for a Randomized Controlled Trial. Liu L et al. 10.2147/NSS.S629630
View abstract

BACKGROUND: The prevalence of chronic insomnia disorder (CID) is relatively high and increases with age. The use of sedatives, along with the incidence of their adverse effects, is also rising, which can easily lead to health risks and negative outcomes. This study aims to evaluate the clinical efficacy and safety of acupuncture-assisted zolpidem tartrate tapering and discontinuation in patients with CID whose insomnia symptoms are clinically stable while taking zolpidem. METHODS: This study is designed as a single-center, single-blind, randomized controlled trial.Ninety participants will be randomly assigned in a 1:1 ratio to either the acupuncture group or the sham acupuncture group. Each participant will undergo 24 sessions of either acupuncture or sham acupuncture, in conjunction with zolpidem tartrate tapering therapy, over a duration of 8 weeks, followed by a 4-week follow-up observation period. The primary outcome is the discontinuation rate of zolpidem tartrate at week 8. Secondary outcomes include the reduction rate of zolpidem tartrate, the discontinuation rates at weeks 10 and 12, frequency of zolpidem tartrate use (nights/week), average daily dose (mg/day), total weekly dose (mg/week), Insomnia Severity Index (ISI), Generalized Anxiety Disorder -7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Short Form Health Survey-12 (SF-12), sleep diary-related indicators, Dysfunctional Beliefs and Attitudes about Sleep Scale -16 (DBAS-16), Epworth Sleepiness Scale (ESS) and emergency medication usage. Adverse events will also be monitored throughout the study. Efficacy analyses will be conducted on the intention-to-treat population. DISCUSSION: The findings of the study may provide preliminary evidence for standardized protocols for reducing and ceasing zolpidem tartrate use through acupuncture assistance. Additionally, this research may offer useful references for patients with CID seeking to safely and effectively reduce or discontinue zolpidem tartrate. These findings may inform future clinical research and larger multicenter confirmatory studies. CLINICAL TRIAL REGISTRATION: ITMCTR2026000497 (Registered on 10 Mar 2026) https://itmctr.ccebtcm.org.cn/mgt/project/view/2031287058080858112.

Nature and science of sleep 2026 PubMed
06 Quality of Life as a Pathway Linking Sleep Quality and Depressive Symptoms in Medical University Students: A Cross-Sectional Study. Liaw JJ et al. 10.2147/JMDH.S655428
View abstract

INTRODUCTION: Depressive symptoms are common among university students and are associated with poor sleep quality. However, it remains unclear whether the association between sleep quality and depressive symptoms is direct or operates through quality of life (QOL). Screen time may also be associated with sleep quality. PURPOSE: This study examined whether QOL mediates the association between sleep quality and depressive symptoms among medical university students, with screen time specified as an upstream behavioral factor of sleep quality. PATIENTS AND METHODS: A cross-sectional study was conducted among 150 students aged 19-24 years. Sleep quality, depressive symptoms, and QOL were assessed using the Pittsburgh Sleep Quality Index, Center for Epidemiologic Studies Depression Scale, and WHOQOL-BREF (Taiwan version), respectively. Partial least squares structural equation modeling with 5,000 bootstrap resamples was used to estimate the structural paths and indirect associations. RESULTS: Longer screen time was associated with poorer sleep quality (β = 0.338, = 0.001). Poorer sleep quality was associated with lower QOL (β = -0.374, < 0.001), whilst higher QOL was associated with fewer depressive symptoms (β = -0.614, < 0.001). Although the total association between sleep quality and depressive symptoms was significant (β = 0.327, 95% bootstrap CI [0.120, 0.477], < 0.001), the direct association was not (β = 0.097, = 0.212). The specific indirect association through QOL was significant (β = 0.229, 95% bootstrap CI [0.119, 0.327], < 0.001), consistent with an indirect-only mediation pattern. CONCLUSION: Sleep quality was indirectly associated with depressive symptoms through QOL within the specified structural model, while longer screen time was associated with poorer sleep quality. These findings highlight QOL as a central consideration in understanding the association between sleep quality and depressive symptoms, alongside screen-use behaviour in relation to sleep health. Longitudinal studies are needed to clarify temporal relationships among these variables.

Journal of multidisciplinary healthcare 2026 PubMed
07 Clinical Positioning of Selective Serotonin Reuptake Inhibitors as Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Comprehensive Review of Mechanisms, Effectiveness, Tolerability, and Treatment Challenges. Alsfouk BA 10.2147/TCRM.S652958
View abstract

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction in which serotonergic signaling contributes to symptom generation and modulation. Selective serotonin reuptake inhibitors (SSRIs) have been proposed as gut-brain neuromodulators because they act on both central and peripheral serotonin pathways. Physiological studies suggest that SSRIs enhance gastric and small bowel transit, although their effects on visceral sensitivity and abdominal pain remain inconsistent. Recent meta-analysis indicates that SSRIs may provide a modest benefit for abdominal pain; however, the certainty of the evidence is low, and no significant improvement has been demonstrated for global IBS symptoms. Findings across randomized controlled trials (RCTs) and meta-analyses remain inconsistent, reflecting substantial heterogeneity in study design, patient populations, and outcome measures. The potential role of SSRIs may differ according to the IBS subtype. By accelerating gastrointestinal transit, SSRIs may be more suitable for constipation-predominant IBS, whereas tricyclic antidepressants (TCAs), which slow transit, may be preferable for diarrhea-predominant IBS. However, evidence supporting subtype-specific efficacy remains limited. Further well-designed RCTs evaluating treatment effects according to IBS phenotype are therefore needed. Current guidelines generally recommend TCAs, which have stronger evidence for efficacy, as first-line neuromodulators and SSRIs as alternative options. In clinical practice, treatment selection should extend beyond efficacy alone and consider bowel habit subtype, predominant symptoms, psychological comorbidities, adverse-effect vulnerability, patient preferences, and the likelihood of treatment acceptance, adherence, and persistence. SSRIs are well tolerated medications and may be particularly useful in selected patients, including those with IBS-constipation or coexisting anxiety, within a personalized, phenotype-informed treatment approach. Prescribers should recognize that patients may face several barriers to accepting and adhering to neuromodulators in IBS including concerns about taking an "antidepressant" for a gastrointestinal disorder, fear of adverse effects, perceived stigma, and misunderstanding of the gut-brain mechanism. Therefore, clinician-patient education and ongoing adherence monitoring are essential.

Therapeutics and clinical risk management 2026 PubMed
08 Comparing the Effects of Premedication With Low-Dose Midazolam, Low-Dose Etomidate, and Transcutaneous Acupoint Electrical Stimulation on Reducing Etomidate-Induced Myoclonic Movements and Pain: A Single-Blind Randomized Clinical Trial. Habibiabadi MR et al. 10.1155/anrp/5199717
View abstract

PURPOSE: Etomidate is a short-acting intravenous hypnotic widely used for anesthetic induction because of its favorable hemodynamic profile. However, etomidate frequently causes injection pain and myoclonic movements, which may lead to clinically relevant complications in susceptible patients. This randomized clinical trial evaluated whether premedication with low-dose midazolam, low-dose etomidate, or transcutaneous acupoint electrical stimulation (TAES) reduces etomidate-induced myoclonus and injection pain compared with control in adults undergoing elective surgery. METHODS: In this single-blind (assessor-blinded), randomized, parallel-group clinical trial, 92 adult patients (18-60 years, ASA physical Status I-II) scheduled for elective surgical procedures at Kashani Hospital (Isfahan, Iran) were allocated to four groups ( = 23 each): control (normal saline), midazolam (0.15 mg/kg), etomidate (0.03 mg/kg), and TAES. TAES was applied bilaterally to the Hegu (LI4), Neiguan (PC6), and Zusanli (ST36) acupoints 30 min before etomidate injection. Injection pain was assessed using the Ambesh Four-Point Behavioral Scale. The presence, severity (0-3), and duration (< 5 s, 5-10 s, > 10 s) of etomidate-induced myoclonic movements were recorded. Hemodynamic parameters were monitored at predefined time points. The primary outcome was the combined incidence of injection pain and myoclonic movements during etomidate administration. Secondary outcomes included myoclonus severity and duration, individual pain and myoclonus scores, periprocedural hemodynamics, and adverse events. Statistical analysis used chi-square or Fisher's exact tests and one-way ANOVA, with < 0.05 considered significant. RESULTS: Ninety-two patients completed the trial (23 per group). Age, height, weight, and baseline hemodynamic parameters were comparable among groups, whereas sex distribution and the prevalence of some comorbidities differed significantly. The incidence of injection pain differed significantly among groups ( = 0.006): 17.4% ( = 4) of patients in the control group exhibited behavioral signs of pain, whereas no injection pain was observed in the midazolam, etomidate, or TAES groups. Myoclonic movements were observed in 60.9% ( = 14) of patients in the control group, compared with 26.1% ( = 6), 39.1% ( = 9), and 34.8% ( = 8) in the etomidate, midazolam, and TAES groups, respectively ( = 0.099). The incidence of the composite primary outcome (defined as injection pain and/or myoclonus) was 60.9% in the control group, compared with 26.1%, 39.1%, and 34.8% in the etomidate, midazolam, and TAES groups, respectively. Compared with control, the risk of the composite endpoint was reduced in all intervention groups (etomidate RR 0.43, 95% CI 0.20-0.92; midazolam RR 0.64, 95% CI 0.35-1.18; TAES RR 0.57, 95% CI 0.30-1.09). The distribution of myoclonus severity ( = 0.180) and duration ( = 0.180) did not differ significantly between groups. No clinically relevant hemodynamic instability, respiratory depression, or major complications were observed. CONCLUSION: Premedication with low-dose midazolam, low-dose etomidate, or TAES completely prevented observable injection pain and produced a clinically meaningful, though statistically nonsignificant, reduction in the incidence of etomidate-induced myoclonic movements compared with control, without compromising hemodynamic stability. These interventions may represent safe and practical strategies to mitigate common adverse effects associated with etomidate; however, larger multicenter trials are warranted to confirm their efficacy for preventing myoclonus. Iranian Registry of Clinical Trials: IRCT20160307026950N70.

Anesthesiology research and practice 2026 PubMed
09 Oviductus Ranae Protein Hydrolysate (ORPH) Ameliorates CUMS-Induced Depressive-Like Behaviors in Mice via Modulation of Gut Microbiota and Metabolic Signatures: An Integrated Multi-Omics Investigation. Liu M et al. 10.1002/fsn3.72572
View abstract

Depression constitutes a significant global health burden, manifesting as persistent low mood, anhedonia, and behavioral disturbances. The pathogenesis of depression is multifactorial, involving hypothalamic-pituitary-adrenal (HPA) axis dysregulation, monoaminergic neurotransmitter abnormalities, and neuroinflammatory processes. protein hydrolysate (ORPH) is an enzymatically hydrolysed extract derived from the dried oviducts of female (, OR). This esteemed traditional Chinese medicine, indigenous to Northeast China, has been utilized as a valuable tonic for centuries. Previous in vivo investigations have demonstrated the anti-neuroinflammatory effects of OR. Chronic unpredictable mild stress (CUMS) is widely used to establish a mouse model of depressive-like phenotypes. This study aimed to investigate whether ORPH could alleviate CUMS-induced depressive-like behaviors in mice and explore its underlying mechanisms from the perspective of gut microbiota and metabolic profiles. A CUMS paradigm was employed to establish a murine model of depression, and the effects of 0.2, 0.4, or 0.8 g/kg ORPH on depressive-like behaviors were systematically evaluated. Biochemical analyses were conducted to quantify inflammatory mediators, neurotransmitters, and HPA axis-associated hormones in murine serum and brain tissue. Multi-omics approaches, encompassing brain tissue metabolomics, fecal metabolomics, and gut microbiota sequencing, were utilized to elucidate key metabolic constituents and signaling pathways implicated in the regulation of cerebral and gut microbial communities. In vivo experiments were conducted to investigate the effects of microbiota depletion and blockade of key metabolites on the therapeutic efficacy of ORPH. Administration of ORPH at doses of 0.2, 0.4, or 0.8 g/kg markedly ameliorated depressive-like behaviors in CUMS-exposed mice. ORPH increased the sucrose preference rate, reduced immobility time in the FST and TST, and shortened the escape latency in the MWM of CUMS mice. Biochemical assays revealed that ORPH attenuated serum and cerebral concentrations of pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α), reduced circulating ACTH and CRH levels, decreased cerebral CORT content, and elevated cerebral 5-HT and NE levels. Moreover, ORPH significantly mitigated hippocampal tissue injury and apoptosis. Metabolomic analyses identified therapeutic modulation of pathways such as sphingolipid and tryptophan metabolism, while gut microbiota profiling highlighted the enrichment of these taxa, including . The protective effect of ORPH was obviously weakened after microbiota depletion, and similar attenuation was observed upon inhibiting tryptophan hydroxylase (TPH) activity and sphingosine kinase (SphK). These findings indicate that ORPH may exert favorable therapeutic potential against CUMS-induced depressive-like phenotypes, possibly through modulation of dysregulated sphingolipid and tryptophan metabolism, which could contribute to the alleviation of neuroinflammation linked to gut microbiota dysbiosis.

Food science & nutrition 2026 Nov PubMed
10 Differential Engagement with Experiential Techniques in Emotion-focused Therapy for Social Anxiety: A Two-case Series from an Indian University Setting. Sharma S et al. 10.1177/02537176261503190
View abstract

Social anxiety disorder (SAD) involves an intense fear of negative evaluation and avoidance of social situations. Emotion-focused therapy (EFT) is an emerging SAD treatment. Still, little is known about client differences in engagement with experiential EFT techniques and whether therapist-observed resistance to these techniques corresponds with therapeutic change. The present study describes a two-case series where two emerging adults with SAD from an Indian university setting received 10 weekly sessions of EFT for social anxiety (EFT-SA). A clinical psychologist diagnosed both participants using ICD-11 criteria alongside elevated Social Interaction Anxiety Scale scores. Participants completed standardized questionnaires measuring social anxiety, emotion regulation, interpersonal functioning, and self-compassion. Assessment was conducted at baseline, termination, and at 3- and 6-month follow-ups. Session-level clinical documentation of engagement and therapist-observed resistance to experiential tasks was also assessed. Both clients improved descriptively across measures; SIAS change was reliable only at 6 months, and scores stayed above clinical cutoffs. Notably, Client B, despite greater clinician-observed resistance to experiential techniques, showed larger gains in self-compassion. This discrepancy is consistent with process research showing that clinicians' real-time impressions of resistance often did not correspond with treatment outcome. Clinically, this points to visible reluctance toward an experiential technique not being, on its own, a sign of global treatment disengagement, and suggests therapists may benefit from distinguishing reluctance toward a specific technique from broader disengagement from therapy. Findings are preliminary and descriptive, drawn from unstandardized clinician observations in two cases, and should be read as hypothesis-generating rather than as evidence of efficacy.

Indian journal of psychological medicine 2026 Nov 11 PubMed
11 Patient Selection for Wide-Awake Local Anesthesia No Tourniquet Surgery: The Role of PROMIS Anxiety and Depression Scores-A Pilot Study. McCarthy B et al. 10.1177/15563316261495944
View abstract

BACKGROUND: Wide-awake local anesthesia with no tourniquet (WALANT) surgery is increasingly used for hand procedures. Yet patient selection remains largely based on surgeon judgment, and evidence-based criteria for identifying patients most likely to tolerate and prefer WALANT are not well defined. Psychological factors such as anxiety and depression may influence the patient's experience during awake surgery. PURPOSE: We sought to better define the factors that may influence patient acceptance of WALANT surgery and inform patient selection. The primary aim was to evaluate whether postoperative Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety and depression scores are associated with willingness to undergo repeat WALANT surgery. A secondary aim was to compare anxiety and depression scores of patients who had undergone WALANT to population norms. METHODS: We conducted a retrospective chart review of 228 patients who underwent WALANT surgery at a single institution, of whom 83 consented to complete a postoperative telephone survey. The survey of the 83 patients who opted to participate included PROMIS Emotional Distress-Anxiety Short Form 7a and the PROMIS Emotional Distress-Depression Short Form 8b and questions on the patient's preference for repeat WALANT. The chart review of the 228 patients collected data on demographics, comorbidities, psychiatric history, and postoperative complications. To ensure that the patients who opted to participate in the survey did not differ significantly from all patients identified, statistical analyses were performed, including -tests and χ or Fisher's exact tests. RESULTS: Of the 83 patients surveyed, 79 (95.2%) said they would undergo WALANT again. The most common reason for saying they would not do so was intraoperative discomfort (50%). Mean PROMIS anxiety (44.59) and depression (43.72) scores were lower than the general population (mean of 50). Demographic factors and comorbidities did not differ significantly between WALANT patients who completed the survey and those who did not. CONCLUSIONS: In this pilot study, most survey respondents said they would be willing to undergo repeat WALANT surgery. PROMIS anxiety and depression scores were not associated with willingness to undergo WALANT in those surveyed. Given the small survey cohort, these findings should be considered preliminary, and larger studies are needed to better define the relationship between anxiety and depression and patient acceptance of WALANT. Among patients who were not willing to undergo repeat WALANT surgery, intraoperative discomfort was the most cited reason, suggesting that optimizing patient comfort during WALANT procedures may be more important for future acceptance than baseline anxiety or depression. LEVEL OF EVIDENCE: Level IV: retrospective chart review and survey.

HSS journal : the musculoskeletal journal of Hospital for Special Surgery 2026 Nov 12 PubMed
12 The mental cost of urban living: neighbourhood deprivation, income, and depressive symptoms in Germany. Farugie A et al. 10.1186/s12889-026-30253-8
View abstract

OBJECTIVE: This study investigates the established associations between neighbourhood socioeconomic deprivation, household income, and depressive symptoms in Germany, and assesses whether these associations differ across settlement structures. Building on the person-in-environment framework, we understand mental health as an emergent outcome of the interplay between individuals and their environments. METHOD: We analysed cross-sectional data from the nationally representative German Health Update 2019/2020 wave of the European Health Interview Survey (GEDA 2019/2020-EHIS) ​ (N = 20,773). Depressive symptoms were measured using Patient Health Questionnaire-8 (PHQ-8). Polynomial regression models tested linear and quadratic associations of neighbourhood deprivation (German Index of Socioeconomic Deprivation, GISD) with depressive symptoms, and their interaction with household income quintiles. Whether settlement type (cities, urban, rural and sparsely populated counties) moderated these associations was tested explicitly using nested interaction models. RESULTS: Higher neighbourhood deprivation was associated with increased depressive symptoms, with a significant quadratic term indicating disproportionately higher symptom severity in highly deprived areas. Household income was inversely associated with depressive symptoms, though its moderation of the deprivation association was only partially supported. Settlement type significantly moderated the deprivation-depression association: the quadratic association was strongest in cities and attenuated, or shifted towards a concave pattern, in less densely populated settlement types. This settlement-related moderation was additionally associated with income, particularly in urban and rural counties, and less consistently in sparsely populated areas. CONCLUSIONS: The psychological burden of socioeconomic deprivation is not uniform, but differs systematically by settlement context and, less consistently, by individual income. These associations were most pronounced, and most clearly evident, in major cities. Addressing mental health inequalities linked to neighbourhood deprivation may therefore benefit from strategies tailored to settlement-specific conditions, alongside broader efforts aimed at individual socioeconomic resources.

BMC public health 2026 Nov 14 PubMed
13 Voice Handicap and Vocal Fatigue, Anxiety, and Depression in Multiple Sclerosis: An Analysis Based on Functional Disability and Disease Progression. Santiago R et al. 10.1016/j.jvoice.2026.10.072
View abstract

OBJECTIVE: To understand how voice handicap, vocal fatigue, anxiety, and depression correlate in individuals with Multiple Sclerosis (MS), based on disease progression and functional disability. METHODS: This observational, cross-sectional study included 52 individuals diagnosed with MS and followed at a specialized care center. Participants were divided into two groups according to functional disability level assessed by the Expanded Disability Status Scale (EDSS): Group 1 (G1), with scores between 0 and 3, and Group 2 (G2), with scores between 3.5 and 7. Sociodemographic and clinical data were collected through a structured questionnaire. In addition, the Voice Handicap Index-10 (VHI-10), Vocal Fatigue Index (VFI), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI) were administered. Correlational and comparative analyses were performed with a significance level of 5% (P < 0.05). RESULTS: There was a predominance of female participants (n = 37; 68.8%) and relapsing-remitting disease course (n = 43; 82.7%). Participants in G1 did not exceed the VHI-10 cutoff score but presented vocal fatigue, with moderate correlations among the instruments, indicating perceived vocal effort and limitations even in cases of lower functional impairment. G2 exceeded the cutoff scores for both VHI-10 and VFI, with significantly higher scores than G1, and also demonstrated stronger correlations with anxiety and depression symptoms, suggesting that in more advanced stages of MS, vocal complaints are more consistently related to the emotional burden of the disease. CONCLUSION: Regardless of the level of functional disability, patients with MS presented self-reported vocal fatigue as well as symptoms of anxiety and depression. However, voice handicap was more evident in the group with greater disease severity.

Journal of voice : official journal of the Voice Foundation 2026 Nov 14 PubMed
14 Self-guided web-based mindfulness and skills-based distress reduction training versus treatment as usual optimised in patients with cancer (Reduct): a multicentre, parallel-group, randomised controlled trial. Bäuerle A et al. 10.1136/bmjment-2026-302908 BMJ mental health 2026 Nov 13 PubMed
15 Roots to Thrive risk and readiness assessment: a practice-based intake and decision-support framework for psychedelic-assisted therapy. Dames SS et al. 10.1136/bmjoq-2026-004275 BMJ open quality 2026 Nov 13 PubMed
16 Mental Health Equality in Poland: Legal and Policy Challenges in the European Context. Widlas-Klimsiak K 10.1163/15718093-bja10187
View abstract

This article examines how Polish psychiatric law and the organisation of care affect the equal exercise of rights by persons with mental disorders or psychosocial disabilities. It combines doctrinal analysis with published implementation evidence, drawing on Polish and international scholarship, the CRPD, the ECHR and relevant EU instruments. The analysis identifies detailed admission safeguards alongside dispersed treatment remedies, broad institution-related grounds for coercion and divided responsibility for community support. These arrangements raise equality concerns where they allow unmet communication or support needs to restrict decision-making, access to review or choice of residence. The article proposes a dedicated procedure for urgent treatment review, narrower coercion powers and clearer duties to secure support beyond hospital care. It distinguishes enforcement of existing rights from legislative reform and assesses those proposals against the differing approaches of the ECtHR and the CRPD Committee to compulsory intervention.

European journal of health law 2026 Nov 13 PubMed
17 Autistic traits among doctors seeking mental health support. Abeyratne L et al. 10.1093/occmed/kqag128
View abstract

BACKGROUND: Neurodevelopmental differences are increasingly recognised in understanding mental health difficulties. However, autism among doctors experiencing mental health problems remains underexplored. AIMS: To assess the prevalence of screening positive for autism among doctors seeking mental health support and examine associations with demographic characteristics, medical speciality, co-occurring mental health difficulties, and neurodevelopmental differences. METHODS: We conducted a cross-sectional analysis of self-reported data from doctors accessing National Health Service Practitioner Health between April and July 2024. The Autism Spectrum Quotient (AQ-10) screened for autism alongside validated measures of depression (PHQ-9), anxiety (GAD-7), psychological distress (CORE-10), and attention-deficit/hyperactivity disorder (ADHD) (ASRS-6). Univariable and multivariable logistic regression analyses were used to assess associations with demographic, clinical, and speciality variables. RESULTS: Of the 946 doctors included, 14% screened positive for autism using the AQ-10. Positive screening was associated with male sex (odds ratio [OR]: 1.71, confidence interval [CI]: 1.14, 2.55), age 22-29 (OR: 1.87, CI: 1.06, 3.30), and working in psychiatry (OR: 2.22, CI: 1.07, 4.63). No other specialty was significantly associated with screening positive for autism. Those who screened positive for autism had significantly higher odds of also screening positive for ADHD (OR 2.22, CI: 1.50, 3.28). CONCLUSIONS: Nearly one in seven doctors screening positive for autism highlights the need for considering the role of neurodevelopmental differences in this professional group. This may help to adapt assessments and interventions to accommodate the neurodivergent needs of the workforce.

Occupational medicine (Oxford, England) 2026 Nov 14 PubMed
18 Depression, Anxiety, and Psychiatric Diagnoses After Radical Cystectomy: Incidence, Timing, and Association with Urinary Diversion Type. Agrawal P et al. 10.1016/j.urology.2026.11.004
View abstract

OBJECTIVES: To characterize the incidence and timing of new psychiatric diagnoses following radical cystectomy and to evaluate their association with urinary diversion type. METHODS: We conducted a retrospective cohort analysis using health records and insurance claims data from the TriNetX Research Network. Cystectomy patients were categorized into neobladder and ileal conduit groups. We compared rates of new and of new or recurrent psychotic, mood, or anxiety disorders at 1 month, 6 months, and 1, 3, and 5 years using propensity matching and relative risk(RR). Kaplan-Meier analysis was used to assess psychiatric diagnosis-free survival. RESULTS: Of 13,318 patients, 2,894 (21.73%) had a neobladder and 10,424 (78.27%) had an ileal conduit. At baseline, the ileal conduit group had higher rates of mood or anxiety disorders. After propensity matching, neobladder patients had higher rates of new mood disorder diagnoses in the first 2-weeks to 1-month post-cystectomy (RR1.81, 95%CI[1.02-3.19]). A sub-analysis demonstrated higher rates of depression at this time (RR1.78, 95%CI[1.04-3.06]). By 6 months, these differences equalized (RR0.85[0.66-1.11] and RR0.90[0.69-1.16]). No differences were observed at 1 year, and by 5 years, rates of new (~14%), or new or recurrent (~25%) psychiatric disorders were similar across diversion types. CONCLUSIONS: Psychiatric illness after radical cystectomy is common regardless of diversion type, affecting one in four patients within five years. The early excess of mood disorder diagnoses among neobladder patients was transient, consistent with an adjustment period. Mental health screening and support should be integrated into preoperative counseling and survivorship care for all cystectomy patients.

Urology 2026 Nov 14 PubMed
19 Dichotomisation and limited antenatal signal constrain prediction of early postpartum depressive symptoms: A secondary analysis of 1634 women. S S et al. 10.1016/j.jad.2026.122731
View abstract

BACKGROUND: Antenatal screening with the Edinburgh Postnatal Depression Scale (EPDS) guides postnatal follow-up. We quantified its performance against early postpartum depressive symptoms and asked whether psychological measures or machine learning recover information discarded at the cutoff. METHODS: Secondary analysis of 1634 women assessed with the EPDS and attachment and coping measures in the third trimester, and with the EPDS again within one week of delivery. Antenatal screening (≥ 12) was evaluated against early postpartum symptoms (≥ 9); risk below the cutoff was characterised; ten algorithms were compared with the antenatal score alone. RESULTS: Sensitivity was 33.4%, specificity 90.9%, positive predictive value 44.0% and negative predictive value 86.5%; 191 of 287 cases screened negative. Among screen-negative women, risk rose from 4.5% (scores 0-2) to 29.2% (9-11; trend z=9.48). An 18-variable model (mean area under the curve, AUC, 0.708) did not differ from the raw score (0.708) in any of 20 repeats (DeLong p=0.53 to 0.97); without the score, 17 variables reached 0.651. A threshold of 5 flagged 54.4% of screen-negative women and captured 81.7% of cases, at 20.3% precision. LIMITATIONS: The outcome, assessed about one week after delivery, overlaps with postpartum blues, and only two timepoints were available. This secondary analysis of one cohort was not preregistered. CONCLUSION: Risk varies continuously and measurably with the antenatal score, but no threshold gives a useful screening programme: a dichotomised screen identifies a minority of cases, and capturing most of the rest approaches universal follow-up.

Journal of affective disorders 2026 Nov 14 PubMed
20 Baseline suicidal thoughts are associated with ECT non-remission and cognitive side effects: A network outcome analysis. Zandstra MG et al. 10.1016/j.jad.2026.122749
View abstract

INTRODUCTION: Electroconvulsive therapy (ECT) is effective for severe depression, yet remission is not universal and cognitive side effects remain a concern. Individual depressive symptoms may provide prognostic information beyond overall severity scores. METHODS: In a multicentre cohort from the Dutch ECT Consortium, we applied network outcome analysis to seven symptoms harmonized across the Hamilton Depression Rating Scale and Montgomery-Åsberg Depression Rating Scale (MADRS). Outcomes were remission (N = 792) and in exploratory analysis, cognitive side effects (N = 100). Robustness was assessed through bootstrapping and sensitivity analyses, including established clinical predictors, an alternative remission definition, and multivariable logistic regression. RESULTS: Suicidal thoughts were associated with lower odds of remission (OR 0.77, bootstrapped confidence interval [bCI] 0.68-0.84) and higher odds of cognitive side effects (OR 1.34, bCI 1.15-2.02), with 98-100% and 72-91% bootstrap edge presence across sensitivity analyses, respectively. Reduced appetite was associated with higher remission odds (OR 1.08, bCI 1.03-1.22), with 70-94% bootstrap edge presence across sensitivity analyses, but the association was absent in the MADRS-specific analysis. Tension/anxiety was associated with higher odds of cognitive side effects (OR 1.26, bCI 1.14-1.92), with 77-84% bootstrap edge presence. After simultaneous covariate adjustment, logistic regression supported associations of suicidal thoughts with both outcomes and tension/anxiety with cognitive side effects; the adjusted cognitive model was exploratory. CONCLUSIONS: Baseline symptoms showed distinct associations with ECT outcomes. Suicidal thoughts were associated with both lower remission likelihood and higher odds of cognitive side effects, suggesting potential relevance for clinical monitoring and counselling.

Journal of affective disorders 2026 Nov 14 PubMed
21 Choroid plexus volume as a marker of chronotherapeutic responsiveness in major depressive disorder. Beatrice B et al. 10.1016/j.bbi.2026.107280
View abstract

Circadian rhythm disruption is a core feature of Major Depressive Disorder (MDD). The choroid plexus (ChP), a circadian-regulated structure involved in cerebrospinal fluid production and immune signalling, has been previously associated with depression and may undergo structural changes in response to chronotherapeutics. The study included 25 patients with MDD and 25 matched healthy controls who underwent MRI. Patients received total sleep deprivation plus light therapy (TSD + LT), consisting of three 36-hour sleep deprivation cycles, each separated by a night of recovery sleep. LT was administered for 30 min every morning. Depressive symptoms, sleep quality, and chronotype were assessed through Beck's Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), and Morningness-Eveningness Questionnaire (MEQ), respectively. ChP volumes were extracted with FreeSurfer and normalized for intracranial volume. Effects of chronotherapeutics were assessed on BDI, PSQI, and ChP volumes, with treatment response as a between-subject factor. The efficacy of treatment was also investigated stratifying for chronotype. Also, group differences in ChP volume and associations with sleep and BDI scores were explored. TSD + LT reduced depressive symptoms and improved sleep quality, with changes in PSQI associated with symptom improvement. Eveningness predicted greater depressive symptom reduction. At baseline, responders already exhibited larger left ChP volume than controls. Following treatment, a treatment × response interaction emerged for right ChP volume, showing a significant reduction in responders. Finally, reductions in both right and left ChP volumes predicted clinical improvement, and sleep quality improvement predicted right ChP volume reduction. This is the first study showing that chronotherapy modulates ChP structure in MDD, suggesting a link between circadian dysregulation and ChP enlargement proportional to clinical improvement and predicted by sleep amelioration. ChP volume may represent a biomarker of treatment responsiveness and circadian realignment.

Brain, behavior, and immunity 2026 Nov 14 PubMed
22 Amitriptyline alters gut microbial composition and compromises host resistance to enteropathogenic infection. Lange E et al. 10.1016/j.bbi.2026.107279
View abstract

Amitriptyline, a tricyclic antidepressant commonly prescribed for depression and various other disorders, has been reported to possess both anti-inflammatory and antimicrobial properties. Paradoxically, clinical evidence suggests that patients with depressive disorders receiving pharmacological treatment exhibit an increased susceptibility to infections, though the mechanisms behind this increased susceptibility remain unclear. This study investigates the impact of amitriptyline on intestinal homeostasis and vulnerability to enteropathogenic infection in a murine model. Oral administration of amitriptyline was found to significantly reduce gut microbial diversity and alter microbiota composition under both homeostatic and infectious conditions, as determined by 16S rRNA gene sequencing. Importantly, there was a marked depletion of butyrate-producing bacteria, accompanied by decreased fecal butyrate levels. Additionally, amitriptyline treatment led to a reduction in colonic regulatory T cells and cytokine production in specific pathogen-free mice, but not in germ-free animals. These results indicate that amitriptyline directly modulates host-microbiota interactions, and suggest that disruption of the gut microbiota may underlie the increased susceptibility to infection. Overall, this study underscores the critical role of the gut microbiome in shaping host responses to pharmacological interventions and identifies it as a potential therapeutic target to mitigate infection risks associated with amitriptyline use.

Brain, behavior, and immunity 2026 Nov 14 PubMed
23 (1)H MRS reveals impact of early adversity and age on neurometabolic profiles in women. Mekle R et al. 10.1016/j.bbi.2026.107284
View abstract

Exposure to early-life stress (ELS), including neglect or abuse, is known for its detrimental effects on brain health. This study investigated how ELS interacts with chronological age to impact on brain metabolism in middle-aged women using proton magnetic resonance spectroscopy (H MRS) at 3 T. High-quality spectra from the hippocampus (HC) and posterior cingulate cortex (PCC) from 75 women, including 53% with ELS exposure before puberty, were analyzed. Generalized additive models assessed non-linear effects of ELS severity and chronological age on neurometabolites related to neuroinflammation and neurotransmitter cycling. Significant interactions emerged for myo-inositol (Ins) in both regions and glutamine (Gln) in the PCC, where greater ELS severity was linked to age-related increases in Ins and Gln concentrations. These results were robust when additionally controlling for symptoms of depression, anxiety, and PTSD, as well as SES, education, menopause status, and smoking. The observed patterns suggest that ELS exposure before puberty, at the older age range, is associated with glial and glutamatergic alterations that are indicative of neuroinflammation, potentially reflecting vulnerability to adverse brain health outcomes.

Brain, behavior, and immunity 2026 Nov 14 PubMed
24 Enhanced functional connectivity in right precuneus after high-frequency repetitive transcranial magnetic stimulation in Parkinson's disease patients with chronic musculoskeletal pain. Chen L et al. 10.1016/j.brainresbull.2026.112218
View abstract

OBJECTIVE: Repetitive transcranial magnetic stimulation (rTMS) can relieve chronic musculoskeletal pain (MSP) in Parkinson's disease (PD), yet the underlying mechanisms remain unclear. METHODS: In this double-blind, sham-controlled trial, 43 PD patients with MSP were randomly assigned to received 10 sessions of neuronavigated 10-Hz rTMS (n=22) or sham stimulation (n=21) over the bilateral primary motor cortex (M1). Clinical assessments were performed at baseline (T0), after the tenth session (T1), and at 1-month (T2) and 3-month (T3) follow-up; functional MRI (fMRI) was acquired at T0 and T1. RESULTS: In the rTMS group, compared to T0, King's Parkinson's Disease Pain Scale (KPPS) and Visual Analog Scale scores decreased significantly at T1, T2, and T3 (p < 0.05). MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III, Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD), and Parkinson's Disease Sleep Scale (PDSS) scores were significantly lower at T1 and T2 than at T0 (p < 0.05), but not at T3 (p > 0.05). No significant correlations were found between KPPS and MDS-UPDRS III, HAMA, HAMD, or PDSS scores (p > 0.05) alterations in the rTMS group. fMRI revealed that patients exhibited decreased amplitude of low-frequency fluctuations in the left cuneus and enhanced functional connectivity between the left cuneus and the right precuneus after rTMS treatment. The sham group showed no significant changes in clinical scores or fMRI. CONCLUSIONS: High-frequency rTMS over bilateral M1 was associated with improvement of MSP in PD, accompanied by reduced local neural activity in the left cuneus and enhanced connectivity between the left cuneus and the right precuneus. These findings are preliminary and hypothesis generating.

Brain research bulletin 2026 Nov 14 PubMed
25 TPA-induced differentiation enhances dopamine and noradrenaline synthesis in SH-SY5Y cells with L-DOPA supplementation. Carvalho C et al. 10.1016/j.pnpbp.2026.112007
View abstract

SH-SY5Y neuroblastoma cells are a widely used in vitro model for studying neuronal differentiation and monoaminergic signalling. However, their ability to produce and release catecholamines under different protocols remains insufficiently characterized. In this study, we analysed the catecholamine profile in undifferentiated cells and in three other differentiation conditions: retinoic acid (RA), 12-O-tetradecanoylphorbol-13-acetate (TPA), and sequential RA/TPA treatment. Catecholamine levels were quantified by high-performance liquid chromatography with electrochemical detection, and enzymatic activities of aromatic L-amino acid decarboxylase (AADC), dopamine β-hydroxylase (DBH), and catechol-O-methyltransferase (COMT) were assessed in TPA differentiated SH-SY5Y. Basal dopamine and noradrenaline levels were very low across all conditions. Supplementation with L-DOPA significantly enhanced catecholamine production, with the strongest effect observed in TPA-differentiated cells. This protocol also increased L-DOPA uptake as well as AADC activity, while DBH and COMT activities remained unchanged. We conclude that TPA-differentiated SH-SY5Y cells supplemented with L-DOPA provide an optimized system for modelling dopaminergic and noradrenergic pathways, supporting their application in toxicology and psychopharmacology studies.

Progress in neuro-psychopharmacology & biological psychiatry 2026 Nov 14 PubMed
26 Interventional Pain Medicine for Women's Health 10.1093/med/9780197820476.001.0001 Unknown Journal 2026 Scholar
27 DEPRESSION AND ANXIETY IN ADULTS WITH STAGE 5 CHRONIC KIDNEY DISEASE RECEIVING RENAL REPLACEMENT THERAPY: A SYSTEMATIC REVIEW J. S. Arum et al. 10.21776/ub.jppbr.2026.007.02.9 Journal of Psychiatry Psychology and Behavioral Research 2026 Scholar
28 The relationship between mental health disorders and LUTS. J. Janssen et al. 10.1016/j.autneu.2026.103422 3 citations Autonomic neuroscience : basic & clinical 2026 Scholar
29 Exploring the role of pain catastrophizing in anxiety and depression among breast cancer survivors Reza Akbarzade et al. 10.4103/jehp.jehp_212_25 Journal of Education and Health Promotion 2026 Scholar
30 Informant discrepancies in adolescent anxiety assessment: The roles of adolescent depression and school avoidance. Blair D. Batky et al. 10.1037/pas0001503 Psychological assessment 2026 Scholar
31 Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the Kingdom of Saudi Arabia M. Alajlan et al. 10.1007/s13555-026-01873-0 Dermatology and Therapy 2026 Scholar
32 Hubungan Depresi, Anxiety, dan Stres dengan Kepatuhan Pengobatan Tuberkulosis Paru Muhammad Akbar Bayu Sujiwo et al. 10.29313/bcsms.v6i1.22261 Bandung Conference Series: Medical Science 2026 Scholar
33 Building Emotional Awareness and Mental Health in Parenting (BEAM): protocol for a parallel-group randomized controlled non-inferiority trial for an app based intervention to improve postpartum mental health and support children’s brain development in Western Canada L. Tomfohr-Madsen et al. 10.1186/s13063-026-09849-3 Trials 2026 Scholar
34 Antidepressant drug use in Europe: past consumption, prescribing patterns and forecast until 2030 L. Bindel et al. 10.1007/s11096-025-02078-9 5 citations International Journal of Clinical Pharmacy 2026 Scholar
35 Predictors of psychiatric emergency department visits within twelve months post-inpatient psychiatric discharge in Alberta, Canada H. Elgendy et al. 10.1371/journal.pone.0351753 PLOS One 2026 Scholar
36 Worst-case scenarios, triggers, and coping strategies among head and neck cancer caregivers. Marilyn Horta et al. 10.1200/jco.2026.44.16_suppl.e18097 Journal of Clinical Oncology 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Mental Health & Depression
  • Week: November 9 – November 16, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 11:13 PM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —